Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients-Reference-Cited by-同舟云学术

Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients

Published:2024-05 Issue: Volume:202 Page:114020
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Barbe Rémy,Belkouchi Younes,Menu Yves,Cohen Romain,David Clemence,Kind Michele,Harguem Sana,Dawi Lama,Hadchiti Joya,Selhane Fatine,Billet Nicolas,Ammari Samy,Bertin Ambroise,Lawrance Littisha,Cervantes Baptiste,Hollebecque Antoine,Balleyguier Corinne,Cournede Paul-Henry,Talbot Hugues,Lassau Nathalie,Andre Thierry^ORCID

Funder

Universite Paris-Saclay

Publisher

Elsevier BV

Reference24 articles.

1. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022;André;Am Soc Clin Oncol Educ Book,2022

2. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer;André;N Engl J Med,2020

3. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study;Diaz LA;Lancet Oncol,2022

4. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment;Taieb;Eur J Cancer Oxf Engl 1990,2022

5. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142;André;Ann Oncol J Eur Soc Med Oncol,2022